Sverige - svenska - Läkemedelsverket (Medical Products Agency)

europharma sverige ab - budesonid; formoterolfumaratdihydrat - inhalationspulver - 320 mikrogram/9 mikrogram/inhalation - budesonid 320 mikrog aktiv substans; laktosmonohydrat hjälpämne; formoterolfumaratdihydrat 9 mikrog aktiv substans - formoterol och budesonid

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

europharma sverige ab - budesonid; formoterolfumaratdihydrat - inhalationspulver - 320 mikrogram/9 mikrogram/inhalation - formoterolfumaratdihydrat 9 mikrog aktiv substans; budesonid 320 mikrog aktiv substans; laktosmonohydrat hjälpämne - formoterol och budesonid

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

europharma sverige ab - budesonid; formoterolfumaratdihydrat - inhalationspulver - 320 mikrogram/9 mikrogram/inhalation - budesonid 320 mikrog aktiv substans; laktosmonohydrat hjälpämne; formoterolfumaratdihydrat 9 mikrog aktiv substans - formoterol och budesonid

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

europharma sverige ab - budesonid; formoterolfumaratdihydrat - inhalationspulver - 320 mikrogram/9 mikrogram/inhalation - formoterolfumaratdihydrat 9 mikrog aktiv substans; budesonid 320 mikrog aktiv substans; laktosmonohydrat hjälpämne - formoterol och budesonid

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklid imaging - diagnostiska radioaktiva läkemedel - detta läkemedel är endast för diagnostisk användning. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - prostata tumörer, kastrering-resistent - terapeutiska radioaktiva läkemedel - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - nepafenak - pain, postoperative; ophthalmologic surgical procedures - ögonsjukdomar - nevanac is indicated for: , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - läkemedel mot obstruktiv lungsjukdom, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - astma - läkemedel mot obstruktiv lungsjukdom, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - läkemedel mot obstruktiv lungsjukdom, - maintenance treatment of asthma in adults whose disease is not adequately controlled.